N. Engl. J. Med. 2017-07-13
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Abstract
Background
Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer.
Methods
We randomly assigned patients with node-positive or high-risk node-negative HER2-positive, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with trastuzumab. We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with placebo.
Results
In the trial population, 63% of the patients who were randomly assigned to receive pertuzumab (2400 patients) or placebo (2405 patients) had node-positive disease and 36% had hormone-receptor-negative disease. Disease recurrence occurred in 171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P=0.045). The estimates of the 3-year rates of invasive-disease-free survival were 94.1% in the pertuzumab group and 93.2% in the placebo group. In the cohort of patients with node-positive disease, the 3-year rate of invasive-disease-free survival was 92.0% in the pertuzumab group, as compared with 90.2% in the placebo group (hazard ratio for an invasive-disease event, 0.77; 95% CI, 0.62 to 0.96; P=0.02). In the cohort of patients with node-negative disease, the 3-year rate of invasive-disease-free survival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard ratio for an invasive-disease event, 1.13; 95% CI, 0.68 to 1.86; P=0.64). Heart failure, cardiac death, and cardiac dysfunction were infrequent in both treatment groups. Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%).
Conclusions
Pertuzumab significantly improved the rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. Diarrhea was more common with pertuzumab than with placebo. (Funded by F. Hoffmann-La Roche/Genentech; APHINITY ClinicalTrials.gov number, NCT01358877 .).
Related Questions
What adjuvant therapy would you offer a post-menopausal CHEK2+ patient with HR+ HER2+ T1bN1 breast cancer and concurrent HR+ HER2- T1N0 disease?
These are hard cases. In general, the HER2 positive disease will take priority. Although it would be ideal to have treated the patient neoadjuvantly to assess response and potentially offer adjuvant TDM-1 per the KATHERINE trial, for now, I would optimize her therapy with adjuvant TCHP for 6 cycles ...
Would you treat an ER/PR+ inflammatory breast cancer that is HER2 2+ by IHC but 5% positive by FISH as HER2 positive?
Yes, because it is inflammatory breast cancer and the standard of care is to include neoadjuvant chemotherapy anyway. In this case, I'd use neoadjuvant TCHP and then retest breast biomarkers at surgery (MRM, with ALND, is standard surgery for inflammatory breast cancer at this time) to see if there ...
Is it acceptable to use TCHP instead of AC-T + trastuzumab as neoadjuvant chemotherapy for HER2+ inflammatory breast cancer?
Yes. With the Neosphere trial demonstrating an impressive PCR rate for the TCHP regimen, the TRAIN-2 trial showing no difference in outcomes with anthracycline containing vs non-anthracycline regimen and the BCIRG-006 trial long term follow showing that only 7 DFS events separating AC-TH and TCH, I ...
How would you approach adjuvant therapy for a premenopausal female with HR+, HER2+ breast cancer with N1mic disease?
Assuming that she has had breast surgery, the adjuvant chemotherapy that I would use in this is weekly paclitaxel at 80 mg/m2 x 12 weeks along weekly trastuzumab x 12 weeks followed every 3-week trastuzumab for a total duration of one year. This regimen with median follow-up of 6.5 years (Tolaney et...
How do you decide between adjuvant trastuzumab vs trastuzumab/pertuzumab in a patient with localized HER2+ breast cancer post neoadjuvant TCHP who has achieved a pCR?
After the TRYPHAENA trial, TCHP became the standard of care neoadjuvant regimen for patients with Her-2+ localized breast cancer that was either LN+ or >2 cm in size primary tumor. This was based on a superior pCR rate of 67% compared to other regimens on this study. The standard of care at this tim...
In patients with stage II-III HER2+ breast cancer who were not treated with neoadjuvant therapy, without having knowledge of response to neoadjuvant therapy (i.e. pCR or not) after chemotherapy, what is your preferred adjuvant HER2 directed therapy?
I largely agree with @Dr. First Last. I am also underwhelmed by the APHINITY data and limit TDM-1 to patients with residual disease after neoadjuvant therapy that includes trastuzumab +/- pertuzumab. And, while I am sure that they exist, I have yet to see the patient to whom I would recommend nerati...
Would you switch to TDM-1 in the adjuvant setting in HER-2 positive breast cancer patients with residual disease after neoadjuvant chemotherapy if neoadjuvant chemotherapy did not include anthracyclines?
The introduction of dual HER2 blockade has significantly increased the pathologic complete response rate of HER2+ disease to neoadjuvant therapy. The TRAIN-2 trial demonstrated that anthracycline based therapy did not increase the PCR rate over a taxane based regimen when dual blockade was used. APH...
How do you manage elderly women with high-risk HER2 positive disease with baseline low ejection fraction?
Aside from avoiding use of an anthracycline, I would treat them with a chemotherapy regimen appropriate to their disease stage and overall medical condition - which may mean using a less intensive or shorter regimen than I would in a younger, fit patient with the same stage of HER2+ disease - plus t...
Is there data supporting the omission of carboplatin from neoadjuvant TCHP therapy for HER2-positive breast cancer to reduce toxicity, particularly in light of findings from the KATHERINE study?
While there is no doubt that the inclusion of carboplatin increases the risk of hematologic and gastrointestinal (mainly diarrhea, but also more nausea) toxicities with TCHP, clinical trial results demonstrate that it also increases pathologic complete response (pCR) rates. No version of THP (using ...
How would you approach a young patient with a prior ER+ HER2- breast CA now local recurrence that now has Her2 positive disease?
For Her-2 positive disease, I would definitely choose chemotherapy with anti Her-2 agent(s). With Her-2 positivity and a young age, the patient is at high risk for recurrence which can be significantly reduced by the addition of anti Her-2 agents to chemotherapy. Although this is a local recurrence,...
For patients with HER2 positive breast cancer s/p neoadjuvant chemotherapy with TC-HP who did not have a complete pathological response at surgery, is there any evidence to use an anthracycline-based chemotherapy after the surgery?
There isn't large comparative data comparing giving anthracyclines vs not in non-PCR patients. In NEOSPHERE all the patients got adjuvant anthracycline after nonanthracycline therapy. It appeared that patients with a PCR did numerically better than non-PCR patients despite all getting anthracyclines...
Do you give radiation concurrently with adjuvant pertuzumab in locally advanced Her2 pos breast cancer?
I am in agreement here. Women with lumpectomy on APHINITY were encouraged to get simlutaneous radiation and traztuzumab/pertuzumab; there did not appear to be any increase in cardiac or other side effects over the traztuzumab arm of the trial in these subjects.
How long do you continue trastuzumab and pertuzumab after lumpectomy if you included both in a neoadjuvant regimen such as TCH-P?
A total of one year for trastuzumab, including the part with chemotherapy, adjuvant or neoadjuvant. The benefit from addition of pertuzumab, as might have been predicted, was very small, since it is very hard to add any sizable benefit to trastuzumab without some logical risk stratification; for ER ...
How do you treat HER2-equivocal breast cancer in the neoadjuvant setting?
If there is no response to AC alone, and the Her2 is equivocal, I would treat with an anti-Her2 regimen such as THP. One could also simply give traztuzumab (possibly with pertuzumab, given the new data from APHINITY to be presented at ASCO 2017) for a year after surgery similar to the HERA trial des...